Navigation Links
Melanoma in Biological Technology

NeoGenomics Reports Second Quarter 2009 Results

... quarter Major new initiative to develop a melanoma FISH Test announced ... We will be developing and validating the melanoma test over the next six months and expect to ... agreement with Abbott can distinguish malignant melanoma from pre-malignant or dysplastic nevi with a ...

Eric D. Whitman, MD to Present on the Delcath PHP System(TM) at the 7th World Congress on Melanoma

... Eric D. Whitman, MD, Director of the Atlantic melanoma Center and a Principal Investigator of Delcath's ... Perfusion for Cutaneous and Uveal Metastatic melanoma , will discuss his experience with the Delcath ... patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an anti-PD-1 ... Safety and Biomarker Data of Ipilimumab in melanoma "Association of baseline ... clinical activity in patients (pts) with advanced melanoma treated with ipilimumab" (Abstract #9008, ...

BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma

... treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting ... options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being ... visceral deposits. About Metastatic melanoma According to the National Cancer Institute, ...

Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium

... Oncolytic Reovirus in Nude Mice Bearing Human melanoma Xenografts" at the 20th EORTC-NCI-AACR Symposium ... October 21-24, 2008. Mice bearing human melanoma tumours each received a single injection ... as a single agent in patients with metastatic melanoma under a Clinical Trials Agreement ...

Independent Monitoring Board Recommends Completion of Accrual to Genasense(R) Phase 3 AGENDA Trial in Advanced Melanoma

... international scientific meeting, Perspectives in melanoma XII, that is scheduled for October 2-4, 2008. ... . About the Perspectives in melanoma Meeting Held annually, Perspectives in melanoma XII will provide an overview of recent advances ...

Oncolytics Biotech Inc. Announces 2008 Second Quarter Results

... work demonstrating that reovirus can kill melanoma cell lines and freshly resected tumour was ... effectively kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... work demonstrating that reovirus can kill melanoma cell lines and freshly resected tumour was ... kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, ...

Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma

... effectively kills and replicates in both human melanoma cell lines and freshly resected tumour. They demonstrated that reovirus melanoma killing is more potent than, and distinct from, ... has a number of mechanisms by which it kills melanoma cell lines and tumours," said Dr. Brad Thompson, ...

DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR

... Non-invasive Genomic Assay for the Detection of melanoma in Suspicious Pigmented Nevi", shows that ... Retrieval) technology to identify melanoma at the earliest stages of disease. The late ... method of identifying disease." Although melanoma accounts for more than 70% of skin cancer ...

Fight Melanoma, With Joe Pesci and Dennis Haysbert on Monday, April 21st

... CA, with a 100% of the proceeds benefiting the melanoma Research Foundation. http://www.melanoma.org ... America). Visit http://www.thebeachtoys.com melanoma is the fastest rising cancer in the U.S. and is ... reported annually. In 1960 the risk of getting melanoma was 1 in 600, but today it is 1 in 74. STUNNING! ...

Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity

... sarcoma. Clear cell sarcoma is a rare type of melanoma (skin cancer) that is difficult to treat. In ... chemotherapy drug used to treat melanoma and other types of cancer, was found to be ... tissues. These include neuroblastomas, glioma, melanoma and carcinoma cell lines of breast, prostate and ...

FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma

... there will be almost 108,000 new cases of melanoma in the United States in 2007, and approximately 8,000 people will die from this disease. melanoma is the deadliest form of skin cancer and the ... with chronic hepatitis C. In the malignant melanoma trial and other clinical studies, ...

DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma

... molecular diagnostics for the early detection of melanoma and other diseases, announced that it has been ... on non-invasive methods for detecting early-stage melanoma and for staging, and claims for monitoring melanoma in a subject. The patent claims the use of ...

BioVex Closes Second Round of Series E Financing

... lead product OncoVex GM-CSF for the treatment of melanoma as well as to complete studies in head and ... completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & ... preparing for an initial registration study in melanoma where multiple responses have been demonstrated ...

Oncolytics Biotech Inc. Announces 2007 Third Quarter Results

... for the first time how reovirus-infected melanoma cells stimulate dendritic cells to prime the ... "Reovirus Infection of Human melanoma Cells Supports Priming of Anti-Tumour Cytotoxic T ... U.K. In this study, the investigators infected melanoma cell lines with reovirus. The reovirus-infected ...

Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers

... -- Every hour of every day, someone dies of melanoma in the United States, making this disease one of ... sexes. Currently, there are more new cases of melanoma than HIV/AIDS. The good news is that when melanoma is found early there is an excellent chance of ...

Reovirus Infection of Melanoma Cells Generates Anti-Tumour Immunity

... Conference entitled "Reovirus Infection of Human melanoma Cells Supports Priming of Anti-Tumour Cytotoxic T ... U.K. In this study, the investigators infected melanoma cell lines with reovirus. The reovirus-infected ... cancer-killing T cells to attack and kill the melanoma cells. "Despite widespread interest in the ...

NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma

... for Overall Survival and Risk of melanoma Metastasizing to Distant Sites REHOVOT, Israel ... indicator test for harmful melanomas. While this melanoma diagnostic test is still in the early ... Rosetta Genomics' Chief Executive Officer. melanoma is one of the leading causes of skin cancer ...

Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting

... "Combination of Oncolytic Reovirus and Rapamycin in a B16.F10 Mouse melanoma Model." In this study, the investigators examined the in vitro and in vivo oncolytic activity of reovirus against the mouse melanoma cell line B16.F10 in combination with the mTOR inhibitor rapamycin. The ...

CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009

... an attractive Phase II development asset that shows activity in metastatic melanoma and promise in breast cancer." commented Dr. Timothy M. Shannon, President ... and report on the final Phase II results of CR011-vcMMAE in metastatic melanoma in the second quarter of 2009 Advance and ...

Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point

... in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The eleven participating cancer centers in this trial ... to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath System is designed ...

Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting

... ------------------------------------------------------------------------- melanoma 3x10(9) 2 PD ... ------------------------------------------------------------------------- melanoma (eye) 1x10(10) 2 PD ...

Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting

... Activity of Oncolytic Reovirus and Cisplatin in a B16.F10 Mouse melanoma Model" is scheduled to be presented October 23, 2008 at the 20th ... activity of reovirus in combination with cisplatin against a mouse melanoma cell line. The researchers demonstrated that the combined therapy results ...

33rd ESMO Congress in Stockholm, 12-16 September 2008

... the Chinese University of Hong Kong. Melanoma Gene variant increases melanoma risk (Embargoed until Monday, 15 September 2008, 15:30 CEST) People ... with stage IV melanoma. The clinical trial is coordinated by the EORTC melanoma Study Group, involving 92 institutions in Europe, the US and Latin ....

Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

... in CLL submitted to FDA -- AGENDA Phase 3 trial of Genasense in melanoma updated at EADO -- Clinical hold on tesetaxel, a leading, clinical-stage ... Genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a Phase 3 trial of Genasense plus chemotherapy, known as AGENDA. AGENDA ...

DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board

... SAB and assist the company as it continues to optimize its novel melanoma assay and develops additional diagnostics using its "tape stripping" ... studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of ...

Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights

... Chairman and Chief Executive Officer. "The Phase 3 trial of Genasense in melanoma has now enrolled more than 25% of its target, we expect accrual completion ... Genasense in Melanoma: Genta is currently enrolling patients with advanced melanoma in a randomized Phase 3 trial of Genasense plus chemotherapy, known as ...

CuraGen Reports Fourth Quarter and Year End 2007 Financial Results

... portion of the Phase I/II clinical trial for patients with metastatic melanoma during the second quarter of 2008; and -- Report updated Phase I/II clinical trial results of CR011-vcMMAE for the treatment of malignant melanoma during the second quarter of 2008. Conference Call Details and Dial-in ...

Advanced Life Sciences Announces Third Quarter 2007 Financial Results

... the FDA for the use of ALS-357 for the topical treatment of metastatic melanoma -- Advanced development of ALS-357 with clinical materials manufactured and placed on stability for the Phase I/II melanoma program; and -- Held two Cethromycin National Advisory Board meetings, ...

BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors

... OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic ... The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II ...

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference

... which binds to MCSP is being developed for the treatment of metastatic melanoma and other cancers expressing MCSP. The first poster presentation shows ... which target the cancer associated antigen MCSP are highly active against melanoma cells by recruiting T cells for efficient tumor cell lysis in vitro ...

BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance

... OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic ... The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II ...

ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery

... diseases based on its groundbreaking ImmunoBody(R) technology platform. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and will enter clinical trials using electroporation technology in early 2010. This press release contains forward-looking information under ...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

... representing a 90 percent premium. With the acquisition Bristol-Myers Squibb gains full rights to ipilimumab, an experimental drug for metastatic melanoma in late stage testing. The companies together have been developing the drug, which is also being studied in lung and prostate cancers. Bristol also ...

CuraGen Reports Second Quarter 2009 Financial Results

... CuraGen in the merger, the proposed settlement of the shareholder class action lawsuits, development opportunities for CR011 in breast cancer and melanoma and the expected timing for presenting updated data for the CR011 breast cancer study, may constitute forward-looking statements within the meaning ...

DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology

... a suspicious lesion. A proprietary 19-gene biomarker is then used to analyze the genetic material to differentiate potentially life-threatening melanoma from other forms of pigmented lesions. Studies to date show the test to be 100% sensitive and 88% specific. Research is also underway to use the ...

Clinical Pharmacology Study With AZILECT(R) (Rasagiline Tablets) Demonstrated It Does Not Increase Tyramine Sensitivity

... planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. All PD patients should be monitored for melanoma (skin cancer) on a regular basis. Side effects seen with AZILECT alone are headache, joint pain, and indigestion; and when taken with levodopa ...

Delcath Systems Granted Third Orphan Drug Designation

... follows two previously granted Delcath orphan drug designations for the drug melphalan for the treatment of patients with metastatic cutaneous melanoma and metastatic ocular melanoma. High dose melphalan, for the treatment of neuroendocrine tumors, is an indication that we have aggressively targeted ...

AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver

... from 20 to 39+ weeks were observed in 9 patients with the following primary cancer types: trachea (39+), tongue (30+), thyroid (29+), prostate and melanoma (28), non-small cell lung cancer (26+), pancreas and 2x colorectal (20). Except for one patient with a background of gastrointestinal problems (GI) ...
Other Contents
(Date:12/17/2014)... The Defense Logistics Agency is insourcing its efforts ... microcircuits from entering into its supply chain. ... initiative dubbed DNA marking. The capability will validate the ... the supply chain. The new quality control measures will ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally transforming ... than at international borders. Over the past decade, ePassports, ... travelers to self process through border control via eGates ... number of airports, seaports, and land borders across the ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
Other TagsOther Tags